BioAtla Inc
A biotechnology company focused on discovering and developing novel antibody-based therapies
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying BioAtla's stock with a target price of $8.67, indicating strong growth potential.
Financial Health
BioAtla is generating modest revenue and cash flow, but faces challenges in overall financial strength.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring BCAB
Pharma M&A Targets: Biotech Stocks to Watch 2025
AbbVie is spending $2.7 billion on external R&D, highlighting a major industry trend of large pharmaceutical companies acquiring innovation. This creates a potential opportunity among the smaller biotech firms that are becoming prime acquisition targets.
Published: October 5, 2025
Explore BasketWhy You’ll Want to Watch This Stock
CAB technology focus
The company’s conditionally active biologics aim to work selectively in tumours; potential benefits exist, but clinical proof is required and outcomes can vary.
Binary clinical catalysts
Trial readouts and regulatory updates can drive meaningful share moves; this creates opportunity but also sharp downside risk if results disappoint.
Partnerships & funding
Collaborations or licensing deals could validate the platform and provide funding, while capital raises may dilute existing holders—assess runway carefully.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals develops treatments for diseases including cystic fibrosis and cancer.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals is a leading biotechnology company that develops and manufactures innovative medicines for serious medical conditions.
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics based on RNA interference (RNAi).
